Vitronectin promotes immunothrombotic dysregulation in the venular microvasculature.
SIRS
immunothrombosis
microvasculature
neutrophils
platelets
systemic inflammation
vitronectin
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
10
2022
accepted:
05
01
2023
entrez:
27
2
2023
pubmed:
28
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Microvascular immunothrombotic dysregulation is a critical process in the pathogenesis of severe systemic inflammatory diseases. The mechanisms controlling immunothrombosis in inflamed microvessels, however, remain poorly understood. Here, we report that under systemic inflammatory conditions the matricellular glycoproteinvitronectin (VN) establishes an intravascular scaffold, supporting interactions of aggregating platelets with immune cells and the venular endothelium. Blockade of the VN receptor glycoprotein (GP)IIb/IIIa interfered with this multicellular interplay and effectively prevented microvascular clot formation. In line with these experimental data, particularly VN was found to be enriched in the pulmonary microvasculature of patients with non-infectious (pancreatitis-associated) or infectious (coronavirus disease 2019 (COVID-19)-associated) severe systemic inflammatory responses. Targeting the VN-GPIIb/IIIa axis hence appears as a promising, already feasible strategy to counteract microvascular immunothrombotic dysregulation in systemic inflammatory pathologies.
Identifiants
pubmed: 36845099
doi: 10.3389/fimmu.2023.1078005
pmc: PMC9945350
doi:
Substances chimiques
Vitronectin
0
Platelet Glycoprotein GPIIb-IIIa Complex
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1078005Informations de copyright
Copyright © 2023 Uhl, Haring, Slotta-Huspenina, Luft, Schneewind, Hildinger, Wu, Steiger, Smiljanov, Batcha, Keppler, Hellmuth, Lahmer, Stock, Weiss, Canis, Stark, Bromberger, Moser, Schulz, Weichert, Zuchtriegel and Reichel.
Déclaration de conflit d'intérêts
Author WW declarers the following conflict of interests: Research grants from Roche, MSD, BMS, and AstraZeneca. Advisory board, lectures, speaker bureaus: Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Janssen, Amgen, Astellas, Illumina, Eisai, Siemens, Agilent, ADC, GSK, and Molecular Health. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Exp Med. 2012 Apr 9;209(4):819-35
pubmed: 22451716
J Clin Invest. 1990 May;85(5):1372-8
pubmed: 1692034
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
Immunity. 2019 Feb 19;50(2):390-402.e10
pubmed: 30709741
J Thromb Haemost. 2005 Oct;3(10):2290-5
pubmed: 16194205
Nat Med. 2009 Apr;15(4):384-91
pubmed: 19305412
Circulation. 2020 Sep 22;142(12):1176-1189
pubmed: 32755393
Arterioscler Thromb Vasc Biol. 2018 Apr;38(4):829-842
pubmed: 29371242
J Thromb Haemost. 2021 Feb;19(2):513-521
pubmed: 33230904
Science. 2014 Dec 5;346(6214):1234-8
pubmed: 25477463
Pharmacol Res. 2020 Aug;158:104950
pubmed: 32450344
Circ Res. 2020 May 8;126(10):1443-1455
pubmed: 32252591
Respir Care. 2020 Jul;65(7):1039-1045
pubmed: 32047121
J Biomed Sci. 2017 Aug 24;24(1):60
pubmed: 28836970
Nat Med. 2010 Aug;16(8):887-96
pubmed: 20676107
Elife. 2017 Jan 16;6:
pubmed: 28092265
Lancet Haematol. 2020 Aug;7(8):e553-e555
pubmed: 32619412
Semin Thromb Hemost. 2011 Jun;37(4):408-24
pubmed: 21805447
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Lancet Haematol. 2020 Aug;7(8):e575-e582
pubmed: 32619411
Nat Rev Immunol. 2013 Jan;13(1):34-45
pubmed: 23222502
Clin Chim Acta. 2020 Aug;507:167-173
pubmed: 32348783
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Thorac Cardiovasc Surg. 2018 Dec;156(6):2155-2167
pubmed: 30005883
J Endovasc Ther. 2003 Feb;10(1):99-110
pubmed: 12751939
Am J Pathol. 2012 Jan;180(1):32-40
pubmed: 22067909
Blood. 2011 Jan 27;117(4):1400-7
pubmed: 20959603
Transl Res. 2020 Nov;225:105-130
pubmed: 32454092
J Leukoc Biol. 2005 Dec;78(6):1318-26
pubmed: 16204641
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Eur Heart J Case Rep. 2020 Dec 25;5(1):ytaa488
pubmed: 33542975
J Thromb Haemost. 2005 May;3(5):875-83
pubmed: 15733060
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619887437
pubmed: 31775524
Nat Med. 2009 Jun;15(6):665-73
pubmed: 19465929
Circulation. 2001 Jan 30;103(4):576-83
pubmed: 11157725
Cell. 2017 Nov 30;171(6):1368-1382.e23
pubmed: 29195076
Nature. 2020 Dec;588(7836):E6
pubmed: 33199918
Blood. 2008 Aug 15;112(4):1461-71
pubmed: 18490516
Thromb Haemost. 2015 Jun;113(6):1289-98
pubmed: 25789443
Haematologica. 2021 Oct 01;106(10):2641-2653
pubmed: 32703799
Blood. 1999 Mar 15;93(6):1825-30
pubmed: 10068653
J Thromb Thrombolysis. 2020 Jul;50(1):54-67
pubmed: 32415579
Blood. 2000 Jan 15;95(2):577-80
pubmed: 10627465
J Clin Invest. 2007 Apr;117(4):953-60
pubmed: 17380206
Nat Med. 2007 Apr;13(4):463-9
pubmed: 17384648
Blood. 2012 Sep 6;120(10):2133-43
pubmed: 22837532
Nat Rev Immunol. 2007 Sep;7(9):678-89
pubmed: 17717539
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973
pubmed: 32311448
Blood. 2004 Aug 15;104(4):1034-41
pubmed: 15069014
Circulation. 2020 May 19;141(20):1648-1655
pubmed: 32200663
PLoS Biol. 2016 May 06;14(5):e1002459
pubmed: 27152726
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Hamostaseologie. 2006 Aug;26(3 Suppl 1):S20-9
pubmed: 16953288
Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12426-30
pubmed: 8618914
Sci Rep. 2019 Nov 4;9(1):15932
pubmed: 31685838
J Clin Invest. 2000 Aug;106(3):385-92
pubmed: 10930441
Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15880-5
pubmed: 20798043
Annu Rev Pathol. 2014;9:181-218
pubmed: 24050624
Thromb Res. 2020 Jun;190:62
pubmed: 32305740
Crit Care. 2018 Mar 8;22(1):60
pubmed: 29519254